Alnylam Pharmaceuticals Inc. gained additional government funding for its biodefense program with a $38.6 million grant from the U.S. Defense Threat Reduction Agency (DTRA) for the development of an RNAi drug to treat viral hemorrhagic fevers. (BioWorld Today)